MYNZ (Mainz Biomed) Forward P/E Multiple

mainzbiomed.com - graphic logo of issuer MYNZ

Oncology diagnostics are crisis-resistant, ensuring a stable cash flow through insurance. The expected P/E multiple for Mainz Biomed N.V. (MYNZ) reflects price dynamics, where 0.00 serves as the current metric level. Molecular laboratories are currently upgrading equipment for the precision analysis of biomaterials. Mainz Biomed N.V. (MYNZ) revenues are based on the sale of non-invasive ColoAlert tests for patients avoiding colonoscopies.

Price to Future Earnings Ratio: mainzbiomed.com (MYNZ) for 07/04/2022 - 03/11/2026

Analytical breakdowns for Mainz Biomed N.V. (MYNZ)

- current price and projected stock value:
Analysis of all company metrics:MYNZ mainzbiomed.com
Signature product of Mainz Biomed NV

The forward P/E determines the ratio of the current market value of Mainz Biomed N.V. (MYNZ) to the expected net income for the following year, allowing investors to assess the risk of overpaying for the asset via the issuer's projected P/E. Amidst a cash gap and high expansion costs for cancer screening systems, this indicator is critically important for understanding the company's timeline to break-even and its reliance on external investments.